Synthetic Cannabinoids Make Fentanyl Overdoses Harder to Reverse with Naloxone

Co-administration of fentanyl with synthetic cannabinoids (JWH-018 or 5F-ADB-PINACA) exacerbated respiratory depression beyond either drug alone. Critically, these combinations conferred resistance to naloxone rescue. Neither naloxone nor the CB1 antagonist rimonabant alone fully reversed the combined respiratory depression. The interaction appeared to involve both pharmacodynamic (receptor-level) and pharmacokinetic (blood-level) mechanisms.

Whole body plethysmography in mice measuring respiratory rate after acute and chronic administration of fentanyl, two structurally distinct synthetic cannabinoids, and their combinations. Antagonist rescue studies with naloxone, rimonabant, and both combined. Blood sampling at peak respiratory depression for pharmacokinetic analysis.

Synthetic cannabinoids are frequently found as adulterants in street opioids, and fentanyl is found in synthetic cannabinoid products. This study provides a biological explanation for the growing phenomenon of naloxone-resistant overdoses.

The finding that synthetic cannabinoid contamination can render naloxone less effective has immediate implications for overdose response protocols. First responders may need to carry CB1 antagonists alongside naloxone in areas where SCRA-contaminated opioids are prevalent.

Mouse model may not perfectly predict human overdose pharmacology. Specific SCRA-fentanyl ratios used may not reflect street drug compositions. Only two SCRAs tested among hundreds of circulating compounds. Pharmacokinetic interactions were suggested but not fully characterized.